Axcynsis gains IND clearance for AT03-65 for CLDN6-positive solid tumors

Jan. 16, 2025

Axcynsis Therapeutics Pte Ltd. has gained IND clearance from the FDA for AT03-65 for the treatment of patients with CLDN6-positive solid tumors. Axcynsis is planning to initiate a phase I trial in the U.S. during the current quarter in patients with advanced CLDN6-positive solid tumors.

BioWorld Science Regulatory Cancer Antibody-drug conjugate Immuno-oncology FDA IND

Today's news in brief

BioWorld

BioWorld briefs for April 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 14, 2025.

Antibodies binding to spike proteins on the surface of SARS-CoV-2 virus

Australian researchers discover new compound to treat long COVID

BioWorld

Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans....

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

FDA wants a shift away from animal testing

BioWorld MedTech

In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower...